Clinical trials: Wet Macular Degeneration
Exudative Macular Degeneration, Diabetic Macular Edema
Analysis of Growth Factors in Patients Undergoing Lucentis or Avastin Injections for Diabetic Macular Edema and Exudative Macular Degeneration
The purpose of this study is to measure biomarkers in the vitreous of patients undergoing Lucentis or avastin treatment.
- Trial name
- NCT01473251
- Testing
- Avastin, Lucentis
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Vitreo-Retinal Associates, Michigan
Exudative Macular Degeneration, Wet Age-related Macular Degeneration
MMP-9 Inhibition for Recalcitrant Wet AMD
Wet (or neovascular) form of age-related macular degeneration (wAMD) is the most common cause of blindness in the Western world.
- Trial name
- NCT04504123
- Testing
- Doxycycline Hyclate
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Iowa
Age-related Macular Degeneration (AMD)
Rehabilitating Vision Loss in Veterans With Age-Related Macular Degeneration
This study will help develop new methods of rehabilitating Veterans with vision loss due to Age-related macular degeneration.
- Trial name
- AMD (NCT05780931)
- Testing
- Study-specific rehabilitation (SSR) procedures
- Where
- United States
- Sponsor
- VA Office of Research and Development
Age Related Macular Degeneration, Pigment Epithelial Detachment
On-label tReatment With Intravitreal Aflibercept injectiOn for Patients With Persistent Pigment epitheliaL Detachments in Neovascular Age Related Macular Degeneration (AMD)
The purpose of this study is to evaluate the efficacy and safety of intravitreal aflibercept injection in a population of neovascular AMD patients that have been previously treated with 2.0 mg ranibizumab for persistent PEDs.
- Trial name
- ROLL (NCT01670162)
- Testing
- Aflibercept
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Tennessee Retina
Age-Related Macular Degeneration
Complement Inhibition With Eculizumab for the Treatment of Non-Exudative Macular Degeneration (AMD)
To evaluate the safety and efficacy of eculizumab for the treatment of dry AMD as evaluated by the change in drusen volume and area of geographic atrophy.
- Trial name
- COMPLETE (NCT00935883)
- Testing
- Eculizumab, Saline
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Philip J. Rosenfeld, MD, PhD
Maculopathy, Maculopathy, Age Related
CRYSTALSIGHT: ''Cohort 1.5" Clinical Investigation Study With OCCUTRACK and Tan Tock Seng Eye Clinic to Further Develop Remote Monitoring of Maculopathy at Home Using Artificial Intelligence for Eye Tracking
The development of a next-generation 'CRYSTALSIGHT' solution using combinations of a novel and cost-effective eye-tracking system with artificial intelligence-based eye-tracking algorithms that detect macular abnormalities and…
- Conditions
- Maculopathy, Maculopathy, Age Related, Macular Degeneration, Age-Related, Diabetic Retinopathy
- Trial name
- NCT07255885
- Testing
- CRYSTALSIGHT Test
- Where
- Singapore
- Volunteers
- 20 people
- Sponsor
- Tan Tock Seng Hospital
Exudative Age-related Macular Degeneration
Macular Pigment Density Evolution in Unilateral Wet AMD Versus Non AMD Patients With or Without Lutein and Zeaxanthine Supplementation
•Purpose: Age-related Macular Degeneration ( AMD) is the leading cause of blindness and visual impairment in industrialized countries.
- Trial name
- NCT01404845
- Testing
- Nutrof Total, food supplement without Lutein and Zeaxanthin
- Where
- 2 sites in France
- Volunteers
- 200 people
- Sponsor
- Affordance
Neovascular (Wet) Age-Related Macular Degeneration
4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration
Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment.
- Trial name
- NCT05197270
- Testing
- 4D-150 IVT, Aflibercept IVT
- Where
- 26 sites in United States, Puerto Rico
- Volunteers
- 215 people
- Sponsor
- 4D Molecular Therapeutics
Wet Age-related Macular Degeneration
Structured Post-marketing Surveillance to Collect the Safety Data of Intravitreal Aflibercept Injection (IVT-AFL) in Patients of Wet Age-related Macular Degeneration During Real World Clinical Practice
The proposed regulatory post-marketing surveillance (PMS) study will be planned to collect the safety data of aflibercept intravitreal injection in patients with wet Age-related Macular Degeneration (AMD) in real-life treatment…
- Trial name
- NCT03290794
- Testing
- Aflibercept (Eylea, BAY86-5321)
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Bayer
AMD
TAB014(Drug Code) in Wet( Neovascular)Age-related Macular Degeneration(AMD) Subjects
Subjects with secondary wet age-related macular degeneration(AMD) or recurrent subfoveal choroidal neovascularization (CNV) in only one study eye will be enrolled into the study.
- Trial name
- NCT03675880
- Testing
- TAB014
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Lee's Pharmaceutical Limited
Neovascular Age-related Macular Degeneration
Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD
The purpose of this study was to compare the efficacy of 0.5 mg ranibizumab versus 2 mg aflibercept bimonthly intravitreal injections on retinal thickness stability.
- Trial name
- SALT (NCT01958918)
- Testing
- Ranibizumab, Aflibercept
- Where
- 68 sites in Austria, Belgium and 8 more
- Volunteers
- 712 people
- Sponsor
- Novartis Pharmaceuticals
Eye Diseases, Macular Degeneration, Wet
Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).
The centre of the retina (macula) at the back of the eye contains cells that give us our central vision that we use for reading and recognising faces.
- Conditions
- Eye Diseases, Macular Degeneration, Wet, Sub-Macular Hemorrhage
- Trial name
- TIGER (NCT04663750)
- Testing
- Pars plana vitrectomy, Intravitreal 2 mg aflibercept will be injected at baseline then monthly for two further doses, then 2-monthly until month 12, subretinal injection of recombinant TPA (Alteplase) up to a maximum of 25 micrograms in 0.2 mls
- Where
- 42 sites in Germany, Ireland and 5 more
- Volunteers
- 210 people
- Sponsor
- King's College Hospital NHS Trust
Age-Related Macular Degeneration
Study of PF-04523655 (REDD14NP) In Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (Wet AMD)
The aim of the study is to evaluate whether PF-04523655 is safe in the treatment of neovascular/wet AMD
- Trial name
- NCT00725686
- Testing
- PF-04523655
- Where
- 11 sites in United States, Israel
- Volunteers
- 54 people
- Sponsor
- Quark Pharmaceuticals
Wet Macular Degeneration
OZURDEX in Age Related Macular Degeneration as Adjunct to Ranibizumab
In the Western World, Age Related Macular Degeneration (ARMD) is a leading cause of blindness. This disease was once thought to be a natural part of aging, but recent research has introduced effective treatments.
- Trial name
- STAR (NCT01243086)
- Testing
- Ranibizumab, OZURDEX
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- McMaster University
Neovascular Age-elated Macular Degeneration (Wet AMD), Exudative Macular Degeneration
Safety and Efficacy of Intravitreal LFG316 in Wet Age Related Macular Degeneration (AMD)
This study will assess the safety and efficacy of LFG316 in patients with age related macular degeneration.
- Trial name
- NCT01535950
- Testing
- LFG316
- Where
- 7 sites in United States
- Volunteers
- 43 people
- Sponsor
- Novartis Pharmaceuticals
Macular Degeneration
A Study of rhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)
This is a phase III, multicenter, randomized, double masked, sham injection-controlled study of the efficacy and safety of intravitreally administered ranibizumab in subjects with subfoveal choroidal neovascularization secondary…
- Trial name
- NCT00090623
- Testing
- rhuFab V2 (ranibizumab)
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Genentech, Inc.
Neovascular Age-related Macular Degeneration
Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMD
AMD (Age Related Macular Degeneration) is the leading cause of severe visual loss and blindness registration in the UK . It is a disease which affects the retina (the nerve and blood vessel network at the back of the eye…
- Trial name
- SAFARI (NCT02161575)
- Testing
- Ranibizumab
- Where
- 28 sites in Germany, United Kingdom
- Volunteers
- 103 people
- Sponsor
- Novartis Pharmaceuticals
Exudative Age-related Macular Degeneration
Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab
Exudative age-related macular degeneration (ARMD) is complicated by choroidal neovascularization (CNV). Although anti-vascular endothelial growth factor treatment is the gold standard treatment, recurrence is the main limitation…
- Trial name
- NCT01810042
- Testing
- ranibizumab
- Where
- 2 sites in South Korea
- Volunteers
- 49 people
- Sponsor
- Pusan National University Hospital
Macular Degeneration, Age-related Maculopathies
Safety and Efficacy Study of rAAV.sFlt-1 in Patients With Exudative Age-Related Macular Degeneration
The study will involve approximately 40 subjects aged 55 or above who have exudative age-related macular degeneration (wet AMD).
- Conditions
- Macular Degeneration, Age-related Maculopathies, Age-related Maculopathy, Maculopathies,Age-related
- Trial name
- AMD (NCT01494805)
- Testing
- rAAV.sFlt-1, Control (ranibizumab alone)
- Where
- Australia
- Volunteers
- 40 people
- Sponsor
- Lions Eye Institute, Perth, Western Australia
Macular Degeneration Exudative Eye Bilateral
The Evolution of Visual Acuity Measured by Electronic Tablet / Computer of Exudative AMD Patients
This pathology, DMLA, whose evolution is chronic, requires regular follow-up and care (IVTs) over a long period (several months or even years).
- Trial name
- NCT03214484
- Testing
- By comparing the evolution of the visual acuity curves., By comparing the evolution of the curves.
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Hospital St. Joseph, Marseille, France